Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2014

Open Access 01-10-2014 | Research article

CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients

Authors: Christian Gytz Ammitzbøll, Rudi Steffensen, Martin Bøgsted, Kim Hørslev-Petersen, Merete L Hetland, Peter Junker, Julia S Johansen, Jan Pødenphant, Mikkel Østergaard, Torkell Ellingsen, Kristian Stengaard-Pedersen

Published in: Arthritis Research & Therapy | Issue 5/2014

Login to get access

Abstract

Introduction

Single-nucleotide polymorphisms (SNPs) in the CRP gene are implicated in the regulation of the constitutional C-reactive protein (CRP) expression and its response to proinflammatory stimuli. Previous reports suggest that these effects may have an impact on clinical decision-making tools based on CRP, such as the Disease Activity Score in 28 joints (DAS28). We aimed to investigate the possible association between seven CRP SNPs, their haplotypes and the serum levels of CRP, as well as DAS28 scores, in two cohorts of untreated active early rheumatoid arthritis (RA) patients followed during their initial treatment.

Methods

Overall, 315 patients with RA from two randomized controlled trials (the CIMESTRA and OPERA trials) who were naïve to disease-modifying antirheumatic drugs and steroids with disease durations less than 6 months were included. Seven CRP SNPs were investigated: rs11265257, rs1130864, rs1205, rs1800947, rs2808632, rs3093077 and rs876538. The genotype and haplotype associations with CRP and DAS28 levels were evaluated using linear regression analysis adjusted for age, sex and treatment.

Results

The minor allele of rs1205 C > T was associated with decreased CRP levels at baseline (P = 0.03), with the TT genotype having a 50% reduction in CRP from 16.7 to 8.4 mg/L (P = 0.005) compared to homozygosity of the major allele, but no association was observed at year 1 (P = 0.38). The common H2 haplotype, characterized by the T allele of rs1205, was associated with a 26% reduction in CRP at baseline (P = 0.043), although no effect was observed at year 1 (P = 0.466). No other SNP or haplotype was associated with CRP at baseline or at year 1 (P ≥0.09). We observed no associations between SNPs or haplotypes and DAS28 scores at baseline or at year 1 (P ≥0.10).

Conclusion

CRP genotype and haplotype were only marginally associated with serum CRP levels and had no association with the DAS28 score. This study shows that DAS28, the core parameter for inflammatory activity in RA, can be used for clinical decision-making without adjustment for CRP gene variants.

Trial registration

The OPERA study is registered at Clinicaltrials.gov (NCT00660647). The CIMESTRA study is not listed in a clinical trials registry, because patients were included between October 1999 and October 2002.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tillett WS, Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930, 52: 561-571. 10.1084/jem.52.4.561.CrossRefPubMedCentralPubMed Tillett WS, Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930, 52: 561-571. 10.1084/jem.52.4.561.CrossRefPubMedCentralPubMed
2.
go back to reference Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812. A published erratum appears in. J Clin Invest. 2003, 112: 299-10.1172/JCI18921C1.CrossRefPubMedCentral Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812. A published erratum appears in. J Clin Invest. 2003, 112: 299-10.1172/JCI18921C1.CrossRefPubMedCentral
3.
go back to reference Bottazzi B, Doni A, Garlanda C, Mantovani A: An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010, 28: 157-183. 10.1146/annurev-immunol-030409-101305.CrossRefPubMed Bottazzi B, Doni A, Garlanda C, Mantovani A: An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010, 28: 157-183. 10.1146/annurev-immunol-030409-101305.CrossRefPubMed
4.
go back to reference Choi J, Joseph L, Pilote L: Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013, 14: 232-244. 10.1111/obr.12003.CrossRefPubMed Choi J, Joseph L, Pilote L: Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013, 14: 232-244. 10.1111/obr.12003.CrossRefPubMed
5.
go back to reference Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK: Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003, 138: 891-897. 10.7326/0003-4819-138-11-200306030-00010.CrossRefPubMed Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK: Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003, 138: 891-897. 10.7326/0003-4819-138-11-200306030-00010.CrossRefPubMed
6.
go back to reference Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA: Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab. 2009, 94: 3251-3258. 10.1210/jc.2008-2406.CrossRefPubMedCentralPubMed Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA: Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab. 2009, 94: 3251-3258. 10.1210/jc.2008-2406.CrossRefPubMedCentralPubMed
7.
go back to reference Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Paré G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M: Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011, 123: 731-738. 10.1161/CIRCULATIONAHA.110.948570.CrossRefPubMedCentralPubMed Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Paré G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M: Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011, 123: 731-738. 10.1161/CIRCULATIONAHA.110.948570.CrossRefPubMedCentralPubMed
8.
go back to reference Suk HJ, Ridker PM, Cook NR, Zee RY: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005, 178: 139-145. 10.1016/j.atherosclerosis.2004.07.033.CrossRefPubMed Suk HJ, Ridker PM, Cook NR, Zee RY: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005, 178: 139-145. 10.1016/j.atherosclerosis.2004.07.033.CrossRefPubMed
9.
go back to reference Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, Pankow JS, Song Q: Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am J Physiol Heart Circ Physiol. 2006, 291: H2752-H2757. 10.1152/ajpheart.01164.2005.CrossRefPubMed Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, Pankow JS, Song Q: Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am J Physiol Heart Circ Physiol. 2006, 291: H2752-H2757. 10.1152/ajpheart.01164.2005.CrossRefPubMed
10.
go back to reference Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: Familial and genetic determinants of systemic markers of inflammation: the NHLBI Family Heart Study. Atherosclerosis. 2001, 154: 681-689. 10.1016/S0021-9150(00)00586-4.CrossRefPubMed Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: Familial and genetic determinants of systemic markers of inflammation: the NHLBI Family Heart Study. Atherosclerosis. 2001, 154: 681-689. 10.1016/S0021-9150(00)00586-4.CrossRefPubMed
11.
go back to reference Shih PB, Manzi S, Shaw P, Kenney M, Kao AH, Bontempo F, Barmada MM, Kammerer C, Kamboh MI: Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol. 2008, 35: 2171-2178. 10.3899/jrheum.080262.CrossRefPubMedCentralPubMed Shih PB, Manzi S, Shaw P, Kenney M, Kao AH, Bontempo F, Barmada MM, Kammerer C, Kamboh MI: Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol. 2008, 35: 2171-2178. 10.3899/jrheum.080262.CrossRefPubMedCentralPubMed
12.
go back to reference Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J. 2006, 27: 1331-1337. 10.1093/eurheartj/ehl018.CrossRefPubMed Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J. 2006, 27: 1331-1337. 10.1093/eurheartj/ehl018.CrossRefPubMed
13.
go back to reference Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Body SC, Shernan SK: C-Reactive protein gene variants are associated with postoperative C-reactive protein levels after coronary artery bypass surgery. BMC Med Genet. 2009, 10: 38-10.1186/1471-2350-10-38.CrossRefPubMedCentralPubMed Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Body SC, Shernan SK: C-Reactive protein gene variants are associated with postoperative C-reactive protein levels after coronary artery bypass surgery. BMC Med Genet. 2009, 10: 38-10.1186/1471-2350-10-38.CrossRefPubMedCentralPubMed
14.
go back to reference D’Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS: C-reactive protein (+1444C > T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis. 2005, 179: 413-417. 10.1016/j.atherosclerosis.2004.10.036.CrossRefPubMed D’Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS: C-reactive protein (+1444C > T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis. 2005, 179: 413-417. 10.1016/j.atherosclerosis.2004.10.036.CrossRefPubMed
15.
go back to reference Grad E, Danenberg HD: C-reactive protein and atherothrombosis: cause or effect?. Blood Rev. 2013, 27: 23-29. 10.1016/j.blre.2012.12.001.CrossRefPubMed Grad E, Danenberg HD: C-reactive protein and atherothrombosis: cause or effect?. Blood Rev. 2013, 27: 23-29. 10.1016/j.blre.2012.12.001.CrossRefPubMed
16.
go back to reference Rhodes B, Fürnrohr BG, Vyse TJ: C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011, 7: 282-289. 10.1038/nrrheum.2011.37.CrossRefPubMed Rhodes B, Fürnrohr BG, Vyse TJ: C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011, 7: 282-289. 10.1038/nrrheum.2011.37.CrossRefPubMed
17.
go back to reference Plant D, Ibrahim I, Lunt M, Eyre S, Flynn E, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A: Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther. 2012, 14: R214-10.1186/ar4052.CrossRefPubMedCentralPubMed Plant D, Ibrahim I, Lunt M, Eyre S, Flynn E, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A: Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther. 2012, 14: R214-10.1186/ar4052.CrossRefPubMedCentralPubMed
18.
go back to reference Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, Stamp L, Steer S, Merriman TR, Vyse TJ: A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med. 2010, 7: e1000341-10.1371/journal.pmed.1000341.CrossRefPubMedCentralPubMed Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, Stamp L, Steer S, Merriman TR, Vyse TJ: A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med. 2010, 7: e1000341-10.1371/journal.pmed.1000341.CrossRefPubMedCentralPubMed
19.
go back to reference Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K: Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014, 73: 654-661. 10.1136/annrheumdis-2012-202735.CrossRefPubMed Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K: Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014, 73: 654-661. 10.1136/annrheumdis-2012-202735.CrossRefPubMed
20.
go back to reference Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Lauridsen UB, Ellingsen T, Hansen GV, Lindegaard H, Vestergaard A, Jurik AG, Østergaard M, Hørslev-Petersen K: Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008, 67: 815-822. 10.1136/ard.2007.076307.CrossRefPubMed Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Lauridsen UB, Ellingsen T, Hansen GV, Lindegaard H, Vestergaard A, Jurik AG, Østergaard M, Hørslev-Petersen K: Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008, 67: 815-822. 10.1136/ard.2007.076307.CrossRefPubMed
21.
go back to reference Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Pødenphant J, Hansen G, Lindegaard H, de Carvalho A, Østergaard M, Hørslev-Petersen K: Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006, 54: 1401-1409. 10.1002/art.21796.CrossRefPubMed Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Pødenphant J, Hansen G, Lindegaard H, de Carvalho A, Østergaard M, Hørslev-Petersen K: Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006, 54: 1401-1409. 10.1002/art.21796.CrossRefPubMed
22.
go back to reference Hetland ML, Østergaard M, Ejbjerg B, Jacobsen S, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Ellingsen T, Lindegaard H, Pødenphant J, Hørslev-Petersen K:Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.Ann Rheum Dis 2012, 71:851-856. A published erratum appears in. Ann Rheum Dis. 2012, 71: 1918-10.1136/ard.2008.099010corr2.CrossRef Hetland ML, Østergaard M, Ejbjerg B, Jacobsen S, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Ellingsen T, Lindegaard H, Pødenphant J, Hørslev-Petersen K:Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.Ann Rheum Dis 2012, 71:851-856. A published erratum appears in. Ann Rheum Dis. 2012, 71: 1918-10.1136/ard.2008.099010corr2.CrossRef
23.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
24.
go back to reference Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010, 69: 631-637. 10.1136/ard.2009.123919.CrossRefPubMedCentralPubMed Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010, 69: 631-637. 10.1136/ard.2009.123919.CrossRefPubMedCentralPubMed
25.
go back to reference Rhodes B, Wong A, Navarra SV, Villamin C, Vyse TJ: Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families. Genes Immun. 2008, 9: 153-160. 10.1038/sj.gene.6364459.CrossRefPubMedCentralPubMed Rhodes B, Wong A, Navarra SV, Villamin C, Vyse TJ: Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families. Genes Immun. 2008, 9: 153-160. 10.1038/sj.gene.6364459.CrossRefPubMedCentralPubMed
26.
go back to reference Ammitzbøll CG, Kjær TR, Steffensen R, Stengaard-Pedersen K, Nielsen HJ, Thiel S, Bøgsted M, Jensenius JC: Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One. 2012, 7: e50585-10.1371/journal.pone.0050585.CrossRefPubMedCentralPubMed Ammitzbøll CG, Kjær TR, Steffensen R, Stengaard-Pedersen K, Nielsen HJ, Thiel S, Bøgsted M, Jensenius JC: Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One. 2012, 7: e50585-10.1371/journal.pone.0050585.CrossRefPubMedCentralPubMed
27.
go back to reference Zecca E, Barone G, Corsello M, Romagnoli C, Tiberi E, Tirone C, Vento G: Reliability of two different bedside assays for C-reactive protein in newborn infants. Clin Chem Lab Med. 2009, 47: 1081-1084. 10.1515/CCLM.2009.246.CrossRefPubMed Zecca E, Barone G, Corsello M, Romagnoli C, Tiberi E, Tirone C, Vento G: Reliability of two different bedside assays for C-reactive protein in newborn infants. Clin Chem Lab Med. 2009, 47: 1081-1084. 10.1515/CCLM.2009.246.CrossRefPubMed
28.
go back to reference Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009, 68: 384-390. 10.1136/ard.2008.088245.CrossRefPubMed Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009, 68: 384-390. 10.1136/ard.2008.088245.CrossRefPubMed
29.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed
30.
go back to reference Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002, 70: 425-434. 10.1086/338688.CrossRefPubMedCentralPubMed Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002, 70: 425-434. 10.1086/338688.CrossRefPubMedCentralPubMed
31.
go back to reference Suk DJ, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM: Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006, 70: 705-716. 10.1111/j.1469-1809.2006.00272.x.CrossRef Suk DJ, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM: Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006, 70: 705-716. 10.1111/j.1469-1809.2006.00272.x.CrossRef
32.
go back to reference Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ: Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet. 2005, 69: 623-638. 10.1111/j.1529-8817.2005.00210.x.CrossRefPubMed Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ: Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet. 2005, 69: 623-638. 10.1111/j.1529-8817.2005.00210.x.CrossRefPubMed
33.
go back to reference Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP: Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA. 2006, 296: 2703-2711. 10.1001/jama.296.22.2703.CrossRefPubMed Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP: Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA. 2006, 296: 2703-2711. 10.1001/jama.296.22.2703.CrossRefPubMed
34.
go back to reference Fransen J, Welsing PMJ, de Keijzer RMH, van Riel PLCM: Development and validation of the DAS28 using CRP [Abstract SP0029]. Ann Rheum Dis. 2003, 62: 10-10.1136/ard.62.7.624.CrossRef Fransen J, Welsing PMJ, de Keijzer RMH, van Riel PLCM: Development and validation of the DAS28 using CRP [Abstract SP0029]. Ann Rheum Dis. 2003, 62: 10-10.1136/ard.62.7.624.CrossRef
35.
go back to reference Roumenina LT, Ruseva MM, Zlatarova A, Ghai R, Kolev M, Olova N, Gadjeva M, Agrawal A, Bottazzi B, Mantovani A, Reid KB, Kishore U, Kojouharova MS: Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry. 2006, 45: 4093-4104. 10.1021/bi052646f.CrossRefPubMed Roumenina LT, Ruseva MM, Zlatarova A, Ghai R, Kolev M, Olova N, Gadjeva M, Agrawal A, Bottazzi B, Mantovani A, Reid KB, Kishore U, Kojouharova MS: Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry. 2006, 45: 4093-4104. 10.1021/bi052646f.CrossRefPubMed
36.
go back to reference Okroj M, Heinegård D, Holmdahl R, Blom AM: Rheumatoid arthritis and the complement system. Ann Med. 2007, 39: 517-530. 10.1080/07853890701477546.CrossRefPubMed Okroj M, Heinegård D, Holmdahl R, Blom AM: Rheumatoid arthritis and the complement system. Ann Med. 2007, 39: 517-530. 10.1080/07853890701477546.CrossRefPubMed
37.
go back to reference Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005, 52: 2293-2299. 10.1002/art.21204.CrossRefPubMed Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005, 52: 2293-2299. 10.1002/art.21204.CrossRefPubMed
38.
go back to reference Knevel R, van Nies JA, le Cessie S, Huizinga TW, Brouwer E, van der Helm-van Mil AH: Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2013, 72: 307-308. 10.1136/annrheumdis-2012-201931.CrossRefPubMed Knevel R, van Nies JA, le Cessie S, Huizinga TW, Brouwer E, van der Helm-van Mil AH: Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2013, 72: 307-308. 10.1136/annrheumdis-2012-201931.CrossRefPubMed
Metadata
Title
CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients
Authors
Christian Gytz Ammitzbøll
Rudi Steffensen
Martin Bøgsted
Kim Hørslev-Petersen
Merete L Hetland
Peter Junker
Julia S Johansen
Jan Pødenphant
Mikkel Østergaard
Torkell Ellingsen
Kristian Stengaard-Pedersen
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-014-0475-3

Other articles of this Issue 5/2014

Arthritis Research & Therapy 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.